How to manage drug-induced arthritis in a patient with tuberculosis (TB) taking first-line anti-TB medications such as isoniazid, rifampicin (Rifadin), pyrazinamide, and ethambutol?

Management of Drug-Induced Arthritis from TB Medications

Pyrazinamide-induced arthralgia should be managed with NSAIDs or colchicine while continuing TB treatment, as joint symptoms are typically due to hyperuricemia and do not require drug discontinuation unless severe. 1

Identifying the Culprit Drug

Pyrazinamide is the most common cause of drug-induced arthritis during TB treatment, occurring through hyperuricemia-mediated joint inflammation rather than true drug allergy 1. This is critical to recognize because:

• Pyrazinamide-related joint symptoms are frequent but manageable and rarely require stopping the drug 1
• True hypersensitivity reactions to rifampicin (causing arthralgia as part of systemic reaction) are rare but potentially severe 2
• Isoniazid and ethambutol rarely cause arthralgias directly 1

Immediate Management Algorithm

Step 1: Assess Severity and Type of Reaction

• If mild-to-moderate joint pain without systemic symptoms: Continue all TB medications and add symptomatic treatment 1
• If severe arthritis with systemic features (rash, angioedema, breathing difficulties, rigors): Stop all TB drugs immediately and hospitalize 2

Step 2: Symptomatic Treatment for Pyrazinamide-Induced Arthralgia

For the typical hyperuricemia-related joint pain:

• Prescribe NSAIDs (ibuprofen or naproxen) for pain control 1
• Consider colchicine if NSAIDs are insufficient or contraindicated 1
• Continue pyrazinamide unless symptoms are intolerable despite treatment 1
• Monitor serum uric acid levels to confirm hyperuricemia as the mechanism 1

Step 3: Drug Rechallenge Protocol (If All Drugs Were Stopped)

If you stopped all medications due to severe reaction, reintroduce drugs sequentially under close monitoring 3:

1. Start with isoniazid at 50 mg/day, increasing to 300 mg/day over 2-3 days if no reaction 3
2. Add rifampicin at 75 mg/day, increasing to full dose (450-600 mg based on weight) over 6-9 days 3
3. Add pyrazinamide last at 250 mg/day, increasing to 1.5-2 g over 2-3 days 3
4. Monitor daily for clinical symptoms and check liver function with each dose escalation 3

Critical pitfall: Never reintroduce drugs without cover of at least two other effective anti-TB agents to prevent resistance development during desensitization 3

Alternative Regimens When Pyrazinamide Must Be Discontinued

If pyrazinamide cannot be tolerated despite symptomatic management:

• Extend treatment to 9 months with rifampicin, isoniazid, and ethambutol (ethambutol for first 2 months only) 3
• This maintains treatment efficacy while avoiding the offending agent 3

For drug-susceptible TB, the standard regimen remains rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, followed by rifampicin and isoniazid for 4 months 4

Special Considerations for True Hypersensitivity

If intradermal or oral challenge testing confirms true rifampicin hypersensitivity (with wheeze, angioedema, or systemic symptoms):

• Switch to streptomycin, isoniazid, ethambutol, and pyrazinamide for 2 months, followed by isoniazid and ethambutol for 12 months 2
• This avoids rifampicin entirely while maintaining treatment efficacy 2
• Ensure directly observed therapy to prevent resistance development with this modified regimen 4

Monitoring During Treatment

• Assess for symptom improvement monthly and evaluate for drug adverse effects 5
• Check liver function if hepatotoxicity symptoms develop (nausea, jaundice, abdominal pain) 3
• Monitor uric acid levels if joint symptoms persist or worsen 1

Key Pitfalls to Avoid

• Never add a single drug to a failing regimen, as this creates monotherapy and rapidly generates resistance 5, 6
• Do not confuse pyrazinamide-induced hyperuricemic arthralgia with true drug allergy—the former is manageable with symptomatic treatment 1, 2
• Never stop treatment prematurely based solely on mild arthralgias without attempting symptomatic management first 1